Preferential utilization of the perforin/granzyme pathway for lysis of Epstein-Barr virus-transformed lymphoblastoid cells by virus-specific CD4+ T cells

Virology

Volumn 287, Issue 1, 2001, Pages 79-88

  Khanolkar, Aaruni ^a   Yagita, Hideo ^b   Cannon, Martin J ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CD4+ T cell; Epstein Barr virus; Fas; Interleukin 4; Perforin; TRAIL

Indexed keywords

CONCANAMYCIN A; FAS ANTIGEN; GRANZYME; HLA ANTIGEN CLASS 2; INTERLEUKIN 4; MONOCLONAL ANTIBODY; PERFORIN; SERINE PROTEINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; CELL CULTURE; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOLYSIS; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; LYMPHOBLASTOID CELL; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; T LYMPHOCYTE; VIRUS TRANSFORMATION;

EID: 0035881710     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2001.1020     Document Type: Article

References (36)

1. EBV persistence in memory B cells in vivo
2. Long-term human B cell lines dependent on interleukin-4 and antibody to CD40
3. Type 1 and Type 2: A fundamental dichotomy for all T cell subsets
4. Long-term T-cell mediated immunity to Epstein-Barr virus in renal-allograft recipients receiving cyclosporin A
5. Expression of the APO-1 antigen in Burkitt lymphoma cell lines correlates with a shift towards a lymphoblastoid phenotype
6. Inhibition of death receptor signaling by FLICE-inhibitory protein as a mechanism for immune escape of tumors
7. + T-cell response to Epstein-Barr virus: T-cell-mediated activation of resting B cells and induction of viral BZLF1 expression
8. + cytotoxic T-lymphocyte clones
9. Epstein-Barr virus-specific T-cell memory in renal-allograft recipients under long-term immunosuppression
10. TRAIL: A molecule with multiple receptors and control mechanisms
11. Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation
12. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity
13. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity
14. Metalloproteinase-mediated release of human Fas ligand
15. + T cell-mediated cytotoxicity
16. Immune regulation in Epstein-Barr virus-associated diseases
17. + T cells use both CD95-dependent and CD95-independent cytolytic mechanisms
18. Viral and immunologic aspects of EBV infection in pediatric liver transplant patients
19. Immunoregulatory abnormalities in patients with EBV-associated B cell lymphoproliferative disorders
20. HLA-DR-antigen-associated restriction of EBV-specific cytotoxic T-cell colonies
21. Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell
22. The inhibition of T-cell-receptor-induced Fas ligand upregulation by cyclosporine and FK506
23. Posttransplantation lymphoproliferative disorders: Current perspectives
24. - T cell response to Epstein-Barr virus (EBV): Implications for the pathogenesis of EBV-associated lymphoproliferative disorders
25. Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis
26. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
27. + cytotoxic T cells against Epstein-Barr virus-immortalized B cell tumors in SCID mice
28. Cytotoxic T lymphocyte response to Epstein-Barr virus
29. + CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing
30. H2 subsets: Doubt no more
31. + T cells
32. How do cytotoxic lymphocytes kill their targets?
33. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
34. Identification and characterization of a new member of the TNF family that induces apoptosis
35. + T cells inhibit growth of Epstein-Barr virus-transformed B cells through CD95-CD95 ligand-mediated apoptosis
36. + CTL directed against herpes simplex virus-infected cells